stockportfolio.pro
DaVita Inc. (DVA)
Healthcare · Medical Care Facilities · NYSE
DaVita Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.71B | $10.88B | $11.40B | $11.39B | $11.55B | $11.62B | $11.61B | $12.14B | $12.82B | $13.64B |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $879.87M | $663.62M | $159.39M | $810.98M | $773.64M | $978.45M | $560.40M | $691.53M | $936.34M | $746.80M |
| Net margin | 8.2% | 6.1% | 1.4% | 7.1% | 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
Source: DaVita Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into DVA stock?
At today's market cap of $12.72B, DaVita Inc. is priced for free-cash-flow growth of about -2.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.31B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 0.1%/yr over the last five fiscal years and revenue 3.4%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of DaVita Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DVA in your portfolio →
DaVita Inc. financial history by metric
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DaVita Inc. — frequently asked questions
What is DaVita Inc.'s revenue?
DaVita Inc. (DVA) reported revenue of $13.64B for fiscal year 2025, up 6.5% from the prior year, according to its SEC filings.
Is DaVita Inc. profitable?
Yes. DVA earned net income of $746.80M in fiscal 2025, a net margin of 5.5%.
What is DVA's P/E ratio?
DaVita Inc. trades at a price-to-earnings ratio of about 19.1 based on the latest data in our nightly-refreshed cache.
How fast is DaVita Inc. growing?
DVA's revenue grew at roughly 3.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does DaVita Inc. have?
As of fiscal year 2025, DVA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is DaVita Inc.'s market cap?
DaVita Inc. (DVA) has a market capitalization of about $12.72B, based on the latest data in our nightly-refreshed cache.
When does DaVita Inc.'s fiscal year end?
DVA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into DVA stock?
At today's market cap of $12.72B, DaVita Inc. is priced for free-cash-flow growth of about -2.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.31B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 0.1%/yr over the last five fiscal years and revenue 3.4%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from DaVita Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.